Addex Therapeutics Ltd Stock Xetra
Stocks
APE
CH0029850754
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 5.23M 6.47M 5.67M 4.89M 9.17M 610M 9.37M 62.81M 24.31M 301M 24.28M 23.75M 1.05B | P/E 2024 |
0.8x | P/E 2025 | -0.88x |
|---|---|---|---|---|---|
| Enterprise Value | 3.62M 4.48M 3.93M 3.39M 6.36M 423M 6.49M 43.54M 16.85M 209M 16.83M 16.46M 725M | EV / Sales 2024 |
5.67x | EV / Sales 2025 | 28.1x |
| Free-Float |
43.94% | Yield 2024 * |
-
| Yield 2025 | - |
Last Transcript: Addex Therapeutics Ltd
| Manager | Title | Age | Since |
|---|---|---|---|
Tim Dyer
CEO | Chief Executive Officer | 58 | 2013-05-31 |
Lénaic Teyssédou
DFI | Director of Finance/CFO | 40 | 2017-05-31 |
Roger Mills
CTO | Chief Tech/Sci/R&D Officer | 69 | 2016-11-27 |
| Director | Title | Age | Since |
|---|---|---|---|
Vincent Lawton
CHM | Chairman | 77 | - |
Tim Dyer
BRD | Director/Board Member | 58 | 2014-12-31 |
Ray Hill
BRD | Director/Board Member | 81 | 2010-05-11 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -3.06% | - | - | 6.47M | |
| -0.48% | +7.20% | -5.08% | +2.45% | 46.2B | |
| +2.19% | +11.71% | +385.81% | +632.13% | 38.71B | |
| +2.53% | +13.93% | +20.85% | -10.61% | 31.9B | |
| +1.65% | +3.61% | +9.98% | +55.42% | 31.12B | |
| -4.16% | -2.58% | +8.74% | +15.22% | 23.77B | |
| -0.32% | +12.96% | - | - | 16.2B | |
| +1.37% | +14.53% | +71.80% | +134.14% | 15.05B | |
| +1.00% | +10.30% | +13.31% | +22.84% | 13.74B | |
| +3.63% | +9.53% | +104.07% | +107.62% | 13.42B | |
| Average | +0.74% | +9.14% | +76.18% | +119.90% | 25.57B | |
| Weighted average by Cap. | +0.75% | +8.71% | +86.69% | +140.75% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 410K 507K 445K 384K 720K 47.86M 735K 4.93M 1.91M 23.65M 1.91M 1.86M 82.02M | 173K 214K 188K 162K 303K 20.18M 310K 2.08M 804K 9.97M 803K 786K 34.58M |
| Net income | 7.06M 8.73M 7.65M 6.61M 12.39M 824M 12.64M 84.81M 32.81M 407M 32.78M 32.07M 1.41B | -6.73M -8.32M -7.3M -6.3M -11.81M -785M -12.06M -80.87M -31.29M -388M -31.26M -30.58M -1.35B |
| Net Debt | -3.3M -4.08M -3.58M -3.09M -5.79M -385M -5.91M -39.66M -15.35M -190M -15.33M -15M -660M | -1.6M -1.98M -1.74M -1.5M -2.82M -187M -2.87M -19.28M -7.46M -92.52M -7.45M -7.29M -321M |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
